In tumor cells with high MDM2 expression, AMG232 enhances p53 activity and inhibits tumor growth.351 AMG232, in combination with immune checkpoint drugs, also enhances T-cell-mediated tumor killing.352 However, high doses of AMG232 may trigger gastrointestinal side effects, neutropenia and leukopenia, which requires further study.353. Here, MDM2 is linked to neoplasm.